Many viruses have evolved, over billions of years, to do exactly what is needed to create effective cancer therapies: kill tumor cells but not normal cells. Neotropix works to harness viruses' natural properties to treat cancer and other diseases that are resistant to available therapeutic methods.
Neotropix began a Phase I/IIa Clinical Trial on our first cancer drug candidate in May, 2006.
We urge you to explore Neotropix and learn about our work in small cell lung cancer and other cancers as a leading biotechnology company in the emerging field of virotherapy.
Neotropix is at the forefront of research and treatment in specific areas such as small cell lung cancer, neuroendocrine non-small cell lung cancer, (including large cell lung cancer), carcinoid and multiple pediatric cancers, such as neuroblastoma, rhabdomyosarcoma, retinoblastoma, medulloblastoma, glioblastoma, rhabdoid tumors, and Wilms’ tumors.